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Abstract
Context
Insulin resistance has been proposed as one of the causes of poor glycemic control in over-
weight/obese youth with type 1 diabetes (T1D). However, the role of adjunctive metformin,
an insulin sensitizer, on glycemic control in these patients is unclear.
Objective
To compare the effect of metformin vs. placebo on hemoglobin A1c (HbA1c), total daily
dose (TDD) of insulin, and other parameters in overweight/obese youth with T1D.
Hypothesis
Adjunctive metformin therapy will improve glycemic control in overweight/obese youth with
T1D.
Design, Setting, and Participants
A 9-mo randomized, double-blind, placebo controlled trial of metformin and placebo in 28
subjects (13m/15f) of ages 10-20years (y), with HbA1c >8% (64 mmol/mol), BMI >85%, and
T1D > 12 months was conducted at a university outpatient facility. The metformin group
consisted of 15 subjects (8 m/ 7f), of age 15.0 ± 2.5 y; while the control group was made up
of 13 subjects (5m/ 8f), of age 14.5 ± 3.1y. All participants employed a self-directed treat-to-
target insulin regimen based on a titration algorithm of (-2)-0-(+2) units to adjust their long-
acting insulin dose every 3rd day from -3 mo through +9 mo to maintain fasting plasma glu-
cose (FPG) between 90–120 mg/dL (5.0–6.7 mmol/L). Pubertal maturation was determined
by Tanner stage.
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Results
Over the course of the 9 months of observation, the between-treatment differences in
HbA1c of 0.4% (9.85% [8.82 to 10.88] for placebo versus 9.46% [8.47 to 10.46] for metfor-
min) was not significant (p = 0.903). There were non-significant reduction in fasting plasma
glucose (189.4 mg/dL [133.2 to 245.6] for placebo versus 170.5 mg/dL [114.3 to 226.7] for
metformin), (p = 0.927); total daily dose (TDD) of short-acting insulin per kg body weight/day
(p = 0.936); and the TDD of long-acting insulin per kg body weight per day (1.15 units/kg/
day [0.89 to 1.41] for placebo versus 0.90 units/kg/day [0.64 to 1.16] for metformin) (p =
0.221). There was no difference in the occurrence of hypoglycemia between the groups.
Conclusions
This 9-month RCT of adjunctive metformin therapy in overweight and obese youth with T1D
resulted in a 0.4% lower HbA1c value in the metformin group compared to the placebo
group.
Trial Registration
ClinicalTrial.gov NCT01334125
Introduction
Obese/overweight youth with type 1 diabetes (T1D) often have suboptimal glycemic control
[1]. Though insulin resistance has been proposed as one of the causes of this poor glycemic
control, the role of adjunctive metformin, an insulin sensitizer, on glycemic control in these
patients is unclear.
Metformin is a biguanide, which acts principally by increasing insulin sensitivity in the liver
by inhibiting hepatic gluconeogenesis and thereby reducing hepatic glucose output [2]. Ran-
domized controlled trials with metformin in adolescents with type 2 diabetes (T2D) reported a
decrease in fasting plasma glucose concentration [3]. However, there have been conflicting
reports from studies in adolescents with T1D [2, 4–7]. The benefit was transient in one study
[7] and no decrease was found in another [4]. The main drawback of these studies was the
small sample size and lack of reporting on long term benefit and safety of adjunctive therapy in
many of them [8].
To address this question, we conducted a 12-month clinical trial consisting of a 3-month
run-in-phase and a 9-month randomized, double-blind, placebo-controlled interventional
period to determine the role of adjunctive metformin therapy on glycemic control in over-
weight/obese youth with T1D. We hypothesized that adjunctive metformin therapy would
improve glycemic control in overweight/obese youth with T1D. The study’s objective was to
compare the effect of adjunctive metformin vs. placebo on glycemic control, body mass index
(BMI), waist circumference (WC), total daily dose (TDD) of insulin, and hypoglycemia in
overweight/obese youth with T1D receiving multiple daily injections of insulin.
Subjects and Methods
The study contract was approved by the Novo Nordisk Inc., on September 16th 2010. The
study protocol (S1 Protocol) was approved by the University of Massachusetts Institutional
Adjunctive Metformin Therapy in Overweight/Obese Youth with T1D
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Review Board (IRB) on January 3rd 2011. Study registration at ClinicalTrials.gov was begun
after the IRB approval and finalized on March 21, 2011. The study’s clinical trial identification
number is NCT01334125. The first study patient was recruited on March 3rd, 2011, after provi-
sional approval had been granted by ClinicalTrials.gov. The study start date of February 2011
on ClinicalTrials.gov registry was not in reference to patient recruitment but to the completion
of both IRB approval and IND exemption from the Food and Drug Administration. The IND
reference ID is 2866975. The last study patient was recruited on August 1, 2013, and the study
was closed on August 8, 2014. The authors confirm that all ongoing and related trials for this
intervention are registered.
Study Design and Setting
This study was an investigator-initiated, single-center, randomized, double-blind, parallel trial
of metformin versus placebo treatments in overweight/obese youth with T1D at a university
teaching hospital.
Subjects
Written informed consent was obtained from each subject’s parent(s) and assent was also
obtained from minors. Inclusion criteria were HbA1c>8% (64 mmol/mol) but<14% (130
mmol/mol), BMI>85th percentile, and T1D>12-month (mo) duration. The initial age of
inclusion was 10–18 years (y), however, this was later increased to 20 y to facilitate enrollment
(S1 Amendment). The diagnosis of T1D was established by the presence of autoantibodies
against islet antigens such as insulin, glutamic acid decarboxylase, and the protein tyrosine
phosphatase-like molecule IA-2. Subjects were excluded if they were pregnant or breastfeeding;
receiving weight-altering therapies; had recurrent hypoglycemia; systemic illnesses; or had a
history of2 episodes of diabetic ketoacidosis in the preceding 12 mo. Five subjects were
excluded based on these criteria (Fig 1). All participants received once-daily subcutaneous
basal insulin injections using detemir insulin; and pre-meal bolus insulin injections using insu-
lin aspart throughout the study period. All participants were overweight or obese pubertal or
post-pubertal subjects with T1D of ages 10–20 y. Fig 1 summarizes the study scheme from
chart review through randomization to study conclusion.
Methods
Participants were evaluated between 8:00–9:00 a.m. following an overnight fast.
Anthropometry. Anthropometric data were collected at enrollment, -3mo, 0 mo, +3mo,
+6mo and at 9 mo. Height was measured to the nearest 0.1 cm using a wall-mounted stadi-
ometer (Holtain Ltd, Crymych, Dyfed, UK). Weight was measured to the nearest 0.1 kg using
an upright scale. BMI was derived using the formula weight/height2 (kg/m2), and expressed as
z-scores. WC was measured to the nearest 0.1 cm at the superior border of the iliac crests.
Biochemical Study. Blood samples for HbA1c estimation were obtained at -3mo, 0 mo,
+3mo, +6 mo and +9 mo, and were analyzed by the Umass Memorial Medical Center Bio-
chemistry laboratory. HbA1c was measured by high pressure liquid chromatography (HPLC)
which has an inter-assay variability of<1.5%, and intra-assay variability of<2.5%, and a nor-
mal range of 4.4.-6.0% [9, 10].
Study Supplies. Metformin and placebo were prepared as identical capsules by Boulevard
Pharmaceutical Compounding Center, Worcester, Massachusetts, USA.
The study drugs (insulin detemir and insulin aspart) were shipped directly from Novo Nor-
disk, Inc., to the Investigational Drug Services (IDS) of the University of Massachusetts Medi-
cal School, which maintained accountability logs for receipt and dispensing of study drugs.
Adjunctive Metformin Therapy in Overweight/Obese Youth with T1D
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Fig 1. CONSORT Flow Diagram.
doi:10.1371/journal.pone.0137525.g001
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Procedure. Following enrollment, all subjects entered a run-in phase of 3-month duration
during which participants were placed on insulin aspart and insulin detemir, and the treat-to-
target insulin regimen (TTIR) started.
• Methodology of Insulin Administration: Treat-to-target insulin regimen(TTIR)
At enrollment, 23 of the 28 subjects received their basal insulin as insulin glargine, while 5
patients received their bolus insulin as insulin lispro. The 23 subjects on insulin glargine were
transitioned to equivalent doses of insulin detemir; while the 5 subjects on insulin lispro were
also transitioned equivalent doses of insulin aspart in a 1:1 ratio. All insulins were administered
as multiple daily injections using the FlexPen insulin injecting device (FlexPen(1), Novo Nor-
disk A/S, Bagsvaerd, Denmark). Patients and their caregivers recorded the total and fractional
daily doses of insulin in patient’s titration data sheets.
To ensure uniformity of insulin administration during the study, participants and their
caregivers used a self-directed titration algorithm of (-2)-0-(+2) scale (Table 1) to adjust the
dose of the subjects’ long-acting insulin, detemir, every 3rd day at bedtime to maintain fasting
plasma glucose (FPG) in the normal range, as follows: increase detemir dose by 2 units if the
average of the 3 prior FPG recordings is>120 mg/dL (6.7 mmol/L); reduce detemir dose by 2
units if the average of 3 FPG readings is<90 mg/dL (5.0 mmol/L), and make no change to the
detemir dose if the average of 3 FPG values is between 90–120 mg/dL (5.0–6.7 mmol/L).
Though the achievement of target HbA1c was encouraged during the run-in phase, it was not
an inclusion/exclusion criterion for randomization.
Subjects’ insulin-to-carbohydrate ratio (ICR), and the correction factor (CF) along with its
component ideal blood glucose (IBG) and insulin sensitivity factor (ISF) were adjusted to
maintain glycemia as shown in Table 2. Based on this titration formula, the average ICR was 1
unit of aspart per 8.0 ± 4.0 g of carbohydrate (CHO); while the average IBG used to determine
the CF was 130.0 ± 10 mg/dL, and the ISF was 34.0 ± 9.0.
Patients returned to the clinic 4 weeks after the initiation of TTIR and then at 12 weeks
intervals till study conclusion. Follow up phone calls were made every 4 weeks to evaluate com-
pliance and possible side effects.
• Methodology of Glucose Data Collection:
Fasting and non-fasting plasma glucose levels were obtained by the patient and/or caregiver
by self-monitoring of patient’s capillary blood glucose using the Precision Xtra Blood Glucose
Monitoring System (Abbott Diabetes Care, Alameda, CA, USA). All participants received a
Study Summary Card containing a synopsis of the daily study guidelines. Parents and study
subjects routinely uploaded subjects’ glucose data to the UMass MyCareTeam [11] website
every 4 weeks for easy review by the study staff. Along with data recorded by families in the
titration algorithm sheets, the MyCareTeam software provided data on hypoglycemic events,
fasting and non-fasting plasma glucose levels, and compliance rate with capillary blood glucose
monitoring.
Table 1. Titration Algorithm for Long-acting Insulin Analog–Detemir.
Titration Algorithm for Long-acting Insulin Analog—Detemir
Average value of fasting plasma glucose for 3
consecutive days
Recommended long-acting insulin dose
adjustments
<5.0 mmol/L (90 mg/dL) subtract 2 units from the total dose of detemir
5.0–6.7 mmol/L (90–120 mg/dL) no adjustments
>6.7 mmol/L (120 mg/dL) add 2 units to the total dose of detemir
doi:10.1371/journal.pone.0137525.t001
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Hypoglycemia was classified as follows: nocturnal [plasma glucose of60 mg/dL (3.3
mmol/L) between 11 PM and 6 AM]; symptoms only (plasma glucose of> 60 mg/dL (3.3
mmol/L) or no measurement); minor (plasma glucose< 60 mg/dL (3.3 mmol/L); and major
(hypoglycemia requiring third party assistance)[12]. To prevent nocturnal hypoglycemia, sub-
jects were advised to maintain a pre-bedtime and nocturnal plasma glucose level of>100 mg/
dL (5.6 mmol/L) (Table 2).
• Nutrition and Exercise:
Each participant received instructions on medical nutrition therapy from a registered dieti-
cian at the beginning of the study. No specific exercise regimen was prescribed to the subjects.
• Randomization:
At the conclusion of the run-in phase, subjects were randomized to either the metformin
arm consisting of treatment with adjunctive metformin at a dose of 1000 mg daily for 9 months,
or the control arm consisting of treatment with similar-appearing placebo capsules daily for 9
months. A metformin dose of 1000 mg was chosen because the Institutional Review Board felt
that a higher dose might lead to severe hypoglycemia in patients receiving insulin therapy.
Randomization-Sequence generation: Randomization was conducted by the Investigational
Drug Services (IDS) of the University of Massachusetts Medical School, using a pre-established
computer-generated sequence located at www.randomization.com. Randomization protocol
was 1:1 (metformin: placebo) and was blocked for every 10 subjects.
Randomization-Allocation concealment: Double-blinded treatments were allocated using
sequentially-numbered drug containers. Concealed treatment allocation was made by IDS,
which secured blinding codes during the trial. IDS maintained a sealed copy of the randomiza-
tion sequence at the investigation site in case of need for emergency unblinding.
Randomization-Implementation: The IDS established the randomization sequence. The
trial endocrinologists enrolled patients to the study. A pharmacist, unconnected with the study,
assigned participants to the groups.
Blinding: Patients and investigators were blinded to the identity of the study medication
and placebo. IDS maintained blinding information throughout the study duration. At study
conclusion, the randomization code was decrypted in a two-step procedure as follows: first
step: treatment A or B; second step: A = metformin and B = placebo. All statistical analyses
were performed after the second step of unblinding.
Objectives. The objective of the trial was to determine the safety and efficacy of adjunctive
metformin therapy compared to placebo during a 9-mo treatment period in overweight/obese
youth with T1D and poor glycemic control.
Outcomes. Primary outcome: Comparison of the baseline-adjusted differences in HbA1c
between the metformin and placebo groups during the trial.
Secondary outcomes: Pre-specified secondary outcomes included additional parameters
that are associated with glycemic control such as total daily dose (TDD) of insulin, TDD of
short-acting insulin, TDD of long-acting insulin, fasting plasma glucose, and hypoglycemia
assessed at baseline and every 3 months till study completion. Anthropometric parameters
including body mass index, and waist circumference were assessed. Safety variables included
pregnancy tests in female subjects of child-bearing age, liver function tests, and creatinine.
Table 2. Summary of Daily PlasmaGlucose Goals.
Time Before breakfast Before lunch or dinner Before bedtime 2 hours after a meal At 3AM
Glucose level (mmol/L) 5.0–6.7 4.44–7.22 > 5.56 <12.22 >5.56
Glucose level (mg/dL) 90–120 80–130 > 100 < 220 > 100
doi:10.1371/journal.pone.0137525.t002
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Ancillary outcomes: Changes in the correction factor (CF), insulin to carbohydrate ratio
(ICR), insulin sensitivity factor (ISF), ideal blood glucose (IBG) during the trial, and the change
in HbA1c during the run-in period.
Protocol Deviations. Treatment was withheld for 2 days in a subject during hospital
admission for the management of severe hypoglycemia; and for 3 days in another patient dur-
ing an admission for acute appendicitis necessitating appendectomy; and in two patients for 2
days each during hospital admissions for the management of diabetic ketoacidosis. All these
subjects were later determined to be in the metformin group. This trial did not enroll the stipu-
lated sample size as the study was stopped before reaching enrollment target because most
youth were reluctant to commit to this long-term study (S1 CONSORT Checklist).
Statistical Analyses
The power calculation for this study was done for a repeated-measures model using GPower
(v.3.1.6, Universität Kiel, Germany). We based this calculation on the level of HbA1c, because
it required the smallest effect difference for a biologically meaningful comparison. We used a
confidence level of 95% (Z (1-α/2) = 1.96 for a two-tailed test) and a statistical power of 80% (Z
(1-β) = 0.84). Our assumptions were that the use of metformin would reduce average HbA1c
values over time by 0.75%, and that the standard deviation for these estimates would be ±1.25.
We also assumed a within subject correlation of 0.500. Our calculated group sizes of 29 individ-
uals for each arm of the trial yielded an actual power of 81.1%.
Subject characteristics were summarized using means and standard deviations (SD).
Group-specific comparisons of anthropometric and biochemical parameters were performed
at baseline using paired t tests or its non-parametric equivalent where indicated. Where doubts
arose about the Normality of our variables, we carried out the above analyses on log-trans-
formed values. Independent proportions (e.g., race, gender) were compared using Fisher’s
exact test. Differences in treatment effects between the randomized groups were evaluated by
comparison of the three study time points (+3mo, +6mo, +9mo), for each of the outcomes of
interest: HbA1c values, fasting blood glucose, total daily dose of insulin, and fractional daily
dose of short- and long-acting insulin. Using the General Linear Model (GLM) procedure,
individual two-way mixed ANOVA models were fitted for each of our outcomes of interest,
with treatment type (metformin or placebo) as the fixed effect and baseline values as
covariates.
We had three missing HbA1c measurements in our dataset. Rather than allowing case dele-
tion, which would have further reduced our power, we imputed the missing values by averaging
the HbA1c measurements immediately before and after the missing datapoints. For this, we
assumed these data were missing completely at random, and considered that our very small
fraction of missing values (0.03%) would not introduce bias. The correlation structure used
was first order autoregressive structure with homogenous variance (ARI). Analyses were based
on the intent-to-treat principle and were performed using SPSS v.22 (IBM Corporation,
Armonk, NY).
Results
Baseline Characteristics
Table 3 shows a comparison of the baseline/randomization characteristics of the metformin
(n = 15) and the placebo (n = 13) groups. The difference in the absolute TDD of insulin per kg
body weight/day appears to be principally due to a higher fractional dose of fast-acting insulin
in the placebo group.
Adjunctive Metformin Therapy in Overweight/Obese Youth with T1D
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Changes in anthropometric parameters
There were no significant differences between the placebo (n = 13) and metformin (n = 15)
groups from baseline to study conclusion for the following parameters: systolic blood pressure
(BP) (p = 0.524), diastolic BP (p = 0.170), weight SDS, WC, and BMI SDS (Fig 2).
Table 3. Anthropometric and Biochemical Characteristics of the Subjects and Controls at Baseline/Randomization. Table 3 shows the group-spe-
cific comparisons of anthropometric and biochemical parameters at baseline using paired t tests or its non-parametric equivalent where indicated. Subject
characteristics were summarized using means ± standard deviations (SD). Independent proportions (e.g., race, gender) were compared using Fisher’s exact
test*. SDS standard deviation score; WC waist circumference; TDD total daily dose; HbA1c hemoglobin A1c. All participants received long-acting insulin
detemir and short-acting insulin aspart. Significant p values are bolded.
Parameters Metformin (n = 15) Placebo (n = 13) p
Age 15.0 ± 2.5 14.5 ± 3.1 0.650
Gender (males) 8/15 (53.3%) 5/13 (38.5%) 0.343*
Ethnicity (Caucasian+Hispanics) 9/15 (60.0%) 11/13 (84.6%) 0.155*
Pubertal (Tanner II-IV) 8/15 (53.3%) 5/13 (38.5%) 0.343*
Height 162.4 ± 11.0 159.1 ± 13.9 0.491
Height SDS -0.1 ± 1.2 0.23 ± 1.1 0.450
Weight 75.5 ± 25.0 70.8 ± 17.9 0.579
Weight SDS 1.5 ± 0.9 1.7 ± 0.5 0.528
BMI 28.2 ± 6.6 27.5 ± 3.7 0.741
BMI SDS 1.6 ± 0.6 1.7 ± 0.3 0.546
WC (cm) 89.7 ± 17.0 97.5 ± 22.7 0.318
Systolic Blood pressure (mmHg) 115.1 ± 18.9 117.5 ± 19.4 0.743
Diastolic Blood pressure (mmHg) 78.5 ± 10.7 78.5 ± 11.9 0.987
Fasting Plasma Glucose (mmol/L) 10.7 ± 3.0 10.8 ± 3.6 0.973
Fasting Plasma Glucose (mg/dL) 193.1 ± 54.1 193.9 ± 64.5 0.973
HbA1c (%) 9.3 ± 1.5 8.7 ± 0.4 0.177
HbA1c (mmol/mol) 77.9 ± 16.5 71.2 ± 4.8 0.177
Duration of disease (years) 5.7 ± 4.4 5.7 ± 5.0 0.991
TDD insulin (units) 84.0 ± 42.9 105.7 ± 43.9 0.198
TDD insulin (units/kg/day) 1.1 ± 0.2 1.44 ± 0.5 0.018
TDD short-acting insulin only (units) 36.7 ± 22.8 49.5 ± 25.8 0.175
TDD short-acting insulin per kg body weight per day (units/kg/day) 0.5 ± 0.2 0.7 ± 0.4 0.067
TDD long-acting insulin only (units) 47.2 ± 23.2 56.2 ± 27.0 0.350
TDD long-acting insulin per kg body weight per day (units/kg/day) 0.6 ± 0.1 0.8 ± 0.3 0.084
doi:10.1371/journal.pone.0137525.t003
Fig 2. Comparison of Anthropometric Parameters during the Trial. This figure shows the changes in anthropometric characteristics between the groups
during the trial. Analysis was performed by repeated measures ANOVA by comparing the 4 study time points (baseline, +3mo, +6mo, +9mo) for each
anthropometric parameter.
doi:10.1371/journal.pone.0137525.g002
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Changes in hemoglobin A1c
Over the course of our 9 months of observation, the between-treatment differences in HbA1c
of 0.39% (9.85% [8.82 to 10.88] for placebo versus 9.46% [8.47 to 10.46] for metformin) was
not significant (p = 0.903) (Fig 3A). In this model, the assumption of sphericity was not fulfilled
(Mauchly’s test p<0.001) so we used the Greenhouse-Geisser correction for our degrees of
Fig 3. Estimated marginal means for changes in outcome parameters A, B, C, D. A. Hemoglobin A1c: Over the course of our 9 months of observation,
the between-treatment differences in HbA1c of 0.4% (9.85% [8.82 to 10.88] for placebo versus 9.46% [8.47 to 10.46] for metformin) was not significant
(p = 0.903). B. Fasting plasma glucose (FPG): For the duration of the interventional phase of the study, the 18.9 mg/dL difference in FPG between the groups
was not significant (189.4 mg/dL [133.2 to 245.6] for placebo versus 170.5 mg/dL [114.3 to 226.7] for metformin), (p = 0.927). C. Total daily dose (TDD) of
long-acting insulin: the 0.25 unit/ kg TDD decrease of long-acting insulin per kg body weight per day (1.15 units/kg [0.89 to 1.41] for placebo versus 0.90
units/kg [0.64 to 1.16] for metformin) was not significant (p = 0.221). D. Total daily dose of short-acting insulin: the 0.01 unit/kg/day for the TDD of short-acting
insulin per kg body weight/day did not vary between the groups (p = 0.936). The difference between the time points was marginally significant (p = 0.090), as
well as the interaction between time and groups (p = 0.079).
doi:10.1371/journal.pone.0137525.g003
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freedom. There was no interaction between time and group (p = 0.290). There were no signifi-
cant changes in A1c in both the metformin and placebo groups at each study time point com-
pared to baseline A1c (Fig 4).
Changes in Fasting Plasma Glucose (FPG)
FPG decreased significantly in subjects who were later randomized to the metformin group
from -3mo to 0 mo during the run-in phase (p = 0.027), but there was no significant change in
FPG in the subjects who were later randomized to the placebo group during the run in phase
(p = 0.127) (Fig 2B).
For the duration of the interventional phase of the study, the 18.9 mg/dL difference in FPG
between the groups was not significant (189.4 mg/dL [133.2 to 245.6] for placebo versus 170.5
mg/dL [114.3 to 226.7] for metformin), (p = 0.927). No significant interaction was found
between time and group (p = 0.089).
Changes in Total Daily Dose of Insulin
The change in absolute total daily dose (TDD) of insulin per kg body weight per day of 0.31
units/kg (1.73 units/kg [1.44 to 2.02] for placebo versus 1.42 units/kg [1.13 to 1.71] for metfor-
min) did not increase significantly over time (p = 0.245), with no interaction between time and
group (p = 0.362).
Similarly, the 0.25 unit/kg TDD decrease of long-acting insulin per kg body weight per day
(1.15 units/kg [0.89 to 1.41] for placebo versus 0.90 units/kg [0.64 to 1.16] for metformin) was
not significant (p = 0.221). Neither was the interaction between time and group (p = 0.269)
(Fig 2C).
The 0.01 unit/kg change in the TDD of short-acting insulin per kg body weight did not vary
between the groups (p = 0.936) (Fig 2D). The difference between the time points was margin-
ally significant (p = 0.090), as well as the interaction between time and groups (p = 0.079).
Changes in the Correction Factor, Insulin to carbohydrate ratio (ICR),
Insulin sensitivity factor (ISF), Ideal Blood glucose (IBG)
A comparison of the changes in insulin-to-carbohydrate ratio (ICR), ideal blood glucose
(IBG), and insulin sensitivity factor (ISF) from baseline at randomization to the end of the
study showed no significant difference in ICR in the metformin group: 1 unit aspart per
8.5 ± 4.0 g of carbohydrate vs. 8.6 ± 4.0, (p = 0.91); or the placebo group 8.15 ± 5.3 vs.
7.62 ± 5.42, (p = 0.304).
Fig 4. Comparison of changes in hemoglobin A1c values between the placebo andmetformin groups during the trial.
doi:10.1371/journal.pone.0137525.g004
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There were equally no differences between baseline and end of study values for ISF in the
placebo group 35.4 ± 13.3 vs. 34.6 ± 12.8, (p = 0.687); or in the metformin group 38.3 ± 13.5 vs.
33.0 ± 10.0, (p = 0.100). Furthermore, the IBG was similar at baseline and at the end of study in
the placebo group: 128.9 ± 11.9 mg/dL vs. 129.2 ± 12.1, (p = 0.819); and also in the metformin
group: 133.0 ± 14.6 vs. 133.0 ± 11.9, (p = 1.00).
A repeated measures ANOVA showed no differences in ISF (p = 0.879), IBG (p = 0.383),
and ICR (p = 0.696) between the placebo and metformin group from baseline to the conclusion
of the study.
Occurrence of Hypoglycemia
Minor hypoglycemia was reported in 3 subjects (20.0%) in the metformin arm, and 2 subjects
(15.4%) in the placebo arm (p = 1.00). Nocturnal hypoglycemia was reported in 2 subjects
(13.3%) in the metformin group, and 2 subjects (15.4%) in the placebo group (p = 1.00). One
instance of major hypoglycemic event occurred in a subject in the metformin arm following a
period of reduced caloric intake. The patient recovered fully without sequalae. No instance of
major hypoglycemia was reported in the placebo arm.
Occurrence of Other Adverse Events
Among the subjects in the metformin arm, there was one subject with acute appendicitis neces-
sitating appendectomy, and single episodes of eye infection that resolved on antibiotic therapy,
a case of mild transient microalbuminuria, and two instances of diabetic ketoacidosis that
occurred during intercurrent illnesses. Among the subjects in the placebo arm, there were sin-
gle episodes of upper respiratory tract infection, pneumonia, otitis media, and hidradenitis. All
subjects recovered from the adverse effects without sequalae.
Compliance
Compliance was monitored during the study by the frequent review of MyCareTeam software
downloads, counting of pills in the dosettes during clinic visits, and review of subjects’ home
documentation of blood glucose data. Analysis of compliance parameters and pharmacy rec-
ords showed no difference in compliance between the two groups. Compliance rate, which was
initially at 90% for both arms during the run-in phase, decreased to 65% at the interval between
the 6th and 9th month visit.
Discussion
In this nine-month randomized, double blind, placebo controlled trial, we report a 0.4% lower
HbA1c value in the metformin group compared to the placebo group. This glycemic finding
was associated with non-significant decreases in FPG, and TDD of long-acting insulin com-
pared to placebo. This clinically significant difference [13] in HbA1c may not have reached sta-
tistical significance due to type 2 error arising from inadequate sample size.
To our knowledge, this is the longest randomized, double-blind, placebo controlled trial of
adjunctive metformin therapy in overweight/obese youth of both genders with T1D. This
study is further distinguished by its employment of a standardized insulin delivery protocol,
the treat-to-target insulin regimen, to ensure uniformity of insulin titration in both arms of the
study; the utilization of MyCareTeam software to capture glucose data for glycemic monitoring
and analysis; and the use of uniform insulin analogs delivered via multiple daily insulin injec-
tions only.
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Published reports on adjunctive metformin therapy in overweight and obese patients with
T1D have reached differing conclusions [1, 2, 6, 14–18]. A recent meta-analysis of 197 studies
on the use of adjunctive metformin therapy in children and adults with T1D concluded that
metformin therapy reduces insulin dose requirements in T1D but not HbA1c value[16]. A
recent 9-mo RCT that examined the effect of metformin for the treatment of hyperandrogen-
ism in 24 female adolescents and young women with T1D, included glycemic endpoints in
their analysis and found no differences in HbA1c and total daily doses of insulin between the
placebo and metformin groups[19]. This study differed from our trial in that the investigators
enrolled only female subjects; used only 850 mg of metformin daily in the treatment arm; and
recruited both normal-weight and overweight/obese subjects. They neither evaluated changes
in fasting glucose levels nor employed a standardized insulin treatment protocol to ensure uni-
formity of glycemic control in both the placebo and metformin groups. They also did not
investigate the changes in the doses of fast-acting- and long acting insulins in both groups.
Another trial, a 6-month RCT of adjunctive metformin in 74 youth with T1D concluded that
metformin therapy reduces insulin dose requirements in T1D but not HbA1c value[1].This
study, though adequately powered, was limited by its relatively short duration.
In contrast, some studies in youth have reported significant reduction in HbA1c in those
who received adjunctive metformin therapy [2, 6, 17, 18]. These studies were, however, limited
by their short duration of 3 months[2, 6], open label design and very small sample size of 9 sub-
jects [17] and 10 subjects[18]. Moreover, the two RCTs that reported reductions in HbA1c [2,
6] did not categorically recruit overweight/obese children and adolescents with T1D, and did
not employ a titration regimen to ensure uniformity of insulin dosing and glycemic control.
Taken together, despite the lack of consensus on the efficacy of adjunctive metformin on
HbA1c in T1D, our study suggests that prolonged treatment with adjunctive metformin could
result in a clinically significant[13] reduction in HbA1c in overweight/obese children and ado-
lescents with T1D.
The elevated mean HbA1c values in our study are similar to the findings from a recent
national report on glycemic control in children and adolescents with T1D which showed
higher mean HbA1c level [8.4 ± 1.4% for whites, 9.6 ± 1.9% for blacks, and 8.7 ± 1.6% for His-
panics] than the recently recommended HbA1c target of<7.5% by the American Diabetes
Association[20]. Furthermore, our finding of suboptimal glycemic control despite increasing
insulin dose in the placebo group is consistent with the results of the Diabetes Control and
Complications Trial (DCCT) [21], which reported that the average of HbA1c values in adoles-
cents with T1D was 1% higher than in adults in both the conventional and intensive treatment
groups, despite receiving more insulin; and attempts to increase insulin doses led to weight
gain and worsening of glycemic control. The proposed mechanism for this deterioration in gly-
cemic control was termed insulin resistance of puberty, which is believed to be driven by the
significantly elevated levels of anti-insulin hormones namely growth hormone and sex steroids,
during the period of active pubertal maturation.
Apart from IR of puberty, other factors may have contributed to the failure to achieve opti-
mal glycemia in this cohort. Differences in subjects’ adherence to insulin therapy may have led
to poor glycemic outcome. Equally, some patients could have adjusted their insulin doses to
maintain glycemic targets that were substantially higher than those directed by the investiga-
tors. It could also be due to a combination of these two factors.
The significant reduction in insulin requirement in our metformin cohort is consistent with
improved insulin sensitivity [22]. The lack of a significant change in ISF in the metformin
group suggests that the mechanism for this reduction in insulin requirement was principally by
increasing hepatic insulin sensitivity through the inhibition of hepatic gluconeogenesis and
consequent reduction in hepatic glucose production [2]. However, though the lack of a
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statistically-significant reduction in HbA1c suggests that insulin resistance may not be the sole
mechanism for poor glycemic control in overweight/obese youth with T1D, our small sample
size may have introduced type 2 statistical errors that prevented the detection of significant dif-
ferences in HbA1c between the groups.
Several socio-demographic and therapeutic factors such as race/ethnicity, socioeconomic
status, parental education, parental involvement in diabetes management, family dynamics,
and whether a patient receives care from an endocrinologist[23] have been associated with
poor glycemic control in youth [23–25]. These variables were considered in our analysis as all
of our subjects received their care from pediatric endocrinologists, had parental involvement in
their diabetes care, were of low to medium socio-economic status, and mostly of white or His-
panic ethnic groups.
This RCT has a number of limitations that should be taken into account in the interpreta-
tion of the results. The small sample size is a major limitation and this could have limited our
ability to detect significant differences in the outcome parameters. Such type 2 errors might
indicate that we had insufficient power to reject the null hypothesis despite the fact that this
hypothesis is false. This is particularly important in interpreting the results that were nearly sig-
nificant such as the change in the TDD of long-acting insulin in which the metformin group
had a consistently lower requirement for long-acting insulin throughout the trial compared to
the placebo group (p = 0.221). It is possible that a significant difference could have been
detected with an adequate sample size.
Secondly, though the significantly reduced insulin requirement in the metformin group was
consistent with increased insulin sensitivity in that cohort, no formal measurement of insulin
resistance using techniques such as hyperinsulinemic euglycemic clamp was conducted. Fur-
thermore, changes in physical activities during the study, which could alter insulin sensitivity,
were not measured; and plasma or urine metformin levels were not obtained to monitor adher-
ence. Intake of calories and macronutrients was not monitored and analyzed as these could
represent strong modifiers of glycemic control in patients with T1D.
The trial was stopped before reaching enrollment target because most youth were reluctant
to commit to this long-term study. An analysis of the characteristics of the 10 subjects who
were consented for the study but not randomized, showed no differences in anthropometric
and glycemic characteristics between the randomized subjects and the 6 dropouts. The remain-
ing 4 subjects were excluded because they either had an HbA1c value of<8% or BMI of<85%
on the day of their scheduled randomization.
The study’s strengths lie in its randomized controlled design, the long duration of interven-
tion, the enrollment criteria, and the use of a common insulin treatment protocol of multiple
daily insulin injections only, thus ensuring a uniformity of timing and delivery of both short-
and long-acting insulins. This is the first trial to employ a standardized insulin titration proto-
col, the treat-to-target insulin regimen, in the investigation of the role of adjunctive metformin
therapy in youth with T1D. The employment of treat-to-target insulin regimen ensured that all
participants used the same algorithm for insulin dose adjustment throughout the duration of
the study. This protocol addressed the problem of the uniformity of insulin administration,
which has been a recurrent confounder in other trials on adjunctive metformin therapy in
T1D. Further strengths of the study include the use of a common insulin analog for the short-
acting and long-acting insulin formulations; the use of a single basal insulin dose given every
evening to ensure accuracy of titration of long-acting insulin dose to FPG levels, and the incor-
poration of the MyCareTeam software to capture glucose readings for the entire duration of
the study. The trial’s retention rate of 78.6% ensured that the completers were representative of
the original cohort. This is the first trial in youth to accurately determine that the differential
increase in insulin requirement in the placebo group was a function of escalations in the dose
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of long-acting insulin, and not the short-acting insulin dose. Thus, the long duration of this
trial ensured that our conclusions were free from initial Hawthorne effects, and the institution
of a standardized insulin delivery protocol allowed conclusions to be drawn on the effect of
adjunctive metformin therapy on glycemic control and insulin requirements that were not pos-
sible in previous studies in this field. Therefore, though this trial’s relatively small sample size
limits the generalizability of these findings, the study’s randomized, placebo-controlled design
and the novel measures implemented to limit confounding variables, ensured the validity of
these results.
Conclusions
In this nine-month randomized, double blind, placebo controlled trial, we report a 0.4% lower
HbA1c value in the metformin group compared to the placebo group. This clinically significant
difference [13] in HbA1c did not reach statistical significance most likely due to type 2 error
arising from inadequate sample size. This reduction in HbA1c suggests that adiposity-associ-
ated insulin resistance may be one of the primary mechanisms for poor glycemic control in
these patients while other factors such as socio-demographic, hormonal, and therapeutic fac-
tors may play a secondary role on glycemic control in this population.
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